Cytokine Release Syndrome clinical trials

Explore recruiting cytokine release syndrome clinical trials.

Recruiting cytokine release syndrome studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cytokine Release Syndrome trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma

Italy, Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Programmed death ligand 1 (PD-L1) PET imaging in patients with (Diffuse) Large B-cell Lymphoma who are treated with CD19-directed CAR T-cell therapy: a pilot study

Netherlands

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase I/II, single arm, open label study of dasatinib as toxicity prophylaxis in the context of therapy with idecabtagene vicleucel in relapsed/refractory multiple myeloma

Germany

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Application of antiCD19 CAR T lymphocytes for the treatment of adult patients with B-cell acute lymphoblastic leukemia with resistance, relapse or detectable measurable residual disease. Phase I/II clinical trial (MERMAID1)

Poland

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

Axicabtagene Ciloleucel CAR T-Cells in Patients with relapsed or refractory primary mediastinal B-Cell Lymphoma

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Single Arm, Open-Label, Phase 1b Trial of Epcoritamab in Pediatric Patients with Relapsed/ Refractory Aggressive Mature B-cell Neoplasms

Italy, Germany, Czechia, Spain, France, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Cytokine Release Syndrome trials by city

Cytokine Release Syndrome in Toronto Cytokine Release Syndrome in Vancouver Cytokine Release Syndrome in Montreal Cytokine Release Syndrome in Calgary Cytokine Release Syndrome in Edmonton Cytokine Release Syndrome in Ottawa Cytokine Release Syndrome in Winnipeg Cytokine Release Syndrome in Quebec City Cytokine Release Syndrome in Hamilton Cytokine Release Syndrome in Kitchener Cytokine Release Syndrome in London Cytokine Release Syndrome in Halifax Cytokine Release Syndrome in New York Cytokine Release Syndrome in Los Angeles Cytokine Release Syndrome in Chicago Cytokine Release Syndrome in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease